Trial Profile
Assessment of LY450139-Mediated Inhibition of Amyloid Beta Formation Determined by 13C6-Leucine In Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Semagacestat (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- Sponsors Eli Lilly and Company
- 18 Oct 2008 New trial record.